

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES March 29, 2011 (Use several sheets if necessary)		ATTORNEY DOCKET NO. 4652.1000-000		APPLICATION NO. 10/568,098	
		FIRST NAMED INVENTOR Steffen Goletz		371(c) Date: June 20, 2006	
		EXAMINER Maria Gomez Leavitt	CONFIRMATION NO. 8158	GROUP 1633	

U.S. PATENT DOCUMENTS

Examiner's Initials	Ref. No.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	A1	US 2006/0292129 A1	12-28-2006	Goletz <i>et al.</i>
	A2	6,984,384 B1	01-10-2006	Subjeck <i>et al.</i>
	A3	7,595,192	09-29-2009	Goletz <i>et al.</i>
	A4			
	A5			
	A6			
	A7			
	A8			
	A9			
	A10			
	A11			
	A12			
	A13			
	A14			
	A15			
	A16			
	A17			
	A18			
	A19			
	A20			

Copies of issued U.S. Patents and Published U.S. Applications are not required and are not being provided. We are not listing separately any prior U.S. Patent Office communications regarding the cited documents because the Examiner has access to any such actions through PAIR.

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES March 29, 2011 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 4652.1000-000		APPLICATION NO. 10/568,098	
	FIRST NAMED INVENTOR Steffen Goletz		371(c) Date: June 20, 2006	
	EXAMINER Maria Gomez Leavitt	CONFIRMATION NO. 8158	GROUP 1633	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Ref. No.	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	B1	WO 94/29469	12-22-1994	Vical Incorporated <i>et al.</i>
	B2	WO 97/00957	01-09-1997	President and Fellows of Harvard College
	B3	WO 03/023023	03-20-2003	Nemon Immuntherapie AG
	B4			
	B5			
	B6			
	B7			
	B8			
	B9			
	B10			
	B11			
	B12			
	B13			
	B14			
	B15			
	B16			
	B17			
	B18			
	B19			
	B20			

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES March 29, 2011 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 4652.1000-000		APPLICATION NO. 10/568,098	
	FIRST NAMED INVENTOR Steffen Goletz		371(c) Date: June 20, 2006	
	EXAMINER Maria Gomez Leavitt	CONFIRMATION NO. 8158	GROUP 1633	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	C1	Anderson, "Human Gene Therapy," <i>Science</i> , 256:808-813 (1992).
	C2	Brummelkamp, <i>et al.</i> , "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," <i>Science</i> , 296:550-553 (2002).
	C3	Elbashir, <i>et al.</i> , "Duplexes of 21-nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells," <i>Nature</i> , 411:494-498 (2001).
	C4	Isner, <i>et al.</i> , "Clinical Evidence of Angiogenesis After Arterial Gene Transfer of phVEGF165 in Patient with Ischaemic Limb," <i>The Lancet</i> , 348:370-374 (1996).
	C5	Novina, <i>et al.</i> , "siRNA-directed Inhibition of HIV-1 Infection," <i>Nature Medicine</i> , 8(7):681-686 (2002).
	C6	Ohyama, <i>et al.</i> , "Dual Roles of Sialyl Lewis X Oligosaccharides in Tumor Metastasis and Rejection by Natural Killer Cells," <i>The EMBO Journal</i> , 18(6):1516-1525 (1999).
	C7	Ohyama, <i>et al.</i> , "Natural Killer Cells Attack Tumor Cells Expressing High Levels of Sialyl Lewis X Oligosaccharides," <i>PNAS</i> , 99(21):13789-13794 (2002).
	C8	Ouagari, <i>et al.</i> , "Glycophorin A Protects K562 Cells from Natural Killer Cell Attack," <i>The Journal of Biological Chemistry</i> , 270(45):26970-26975 (1995).
	C9	Owens, <i>et al.</i> , "Identification of Two Short Internal Ribosome Entry Sites Selected from Libraries of Random Oligonucleotides," <i>PNAS</i> , 98(4):1471-1476 (2001).
	C10	Paddison, <i>et al.</i> , "Short Hairpin Rnas (shRNAs) Induce Sequence-Specific Silencing in Mammalian Cells," <i>Genes & Development</i> , 16:948-958 (2002).
	C11	Sivanandham, <i>et al.</i> , "Cancer Vaccines: Clinical Applications," <i>Principles and Practice of the Biologic Therapy of Cancer</i> , Third Ed., S. Rosenberg, pp. 632-647, Lippincott Williams & Wilkins, Philadelphia, PA (2002).
	C12	Verma, <i>et al.</i> , "Gene Therapy – Promises, Problems and Prospects," <i>Nature</i> , 389:239-242 (1997).
	C13	Mivechi, "Heat Sensitivity, Thermotolerance, and Profile of Heat Shock Protein Synthesis of Human Myelogenous Leukemias," <i>Cancer Research</i> , 49:1954-1958 (1989).
	C14	Lozzio and Lozzio, "Human Chronic Myelogenous Leukemia Cell-Line with Positive Philadelphia Chromosome," <i>Blood</i> , 45(3):321-334 (1975).
	C15	Yoshima, <i>et al.</i> , "Heat Shock Factor 1 Mediates Hemin-Induced <i>hsp70</i> Gene Transcription in K562 Erythroleukemia Cells," <i>JBC</i> , 273(39):25466-25471 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES March 29, 2011 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 4652.1000-000		APPLICATION NO. 10/568,098	
	FIRST NAMED INVENTOR Steffen Goletz		371(c) Date: June 20, 2006	
	EXAMINER Maria Gomez Leavitt		CONFIRMATION NO. 8158	GROUP 1633

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	C16	Samali, <i>et al.</i> , "Thermotolerance and Cell Death are Distinct Cellular Responses to Stress: Dependence on Heat Shock Proteins," <i>FEBS Letters</i> , 461(3):306-310 (1999).
	C17	Huang, <i>et al.</i> , "Heat-Induced Gene Expression as a Novel Targeted Cancer Gene Therapy Strategy," <i>Cancer Research</i> , 60:3435-3439 (2000).
	C18	Office Action, U.S. Application No. 10/524,738, date of mailing October 5, 2006. *
	C19	Office Action, U.S. Application No. 10/524,738, date of mailing December 14, 2006. *
	C20	Office Action, U.S. Application No. 10/524,738, date of mailing August 10, 2007.*
	C21	Office Action, U.S. Application No. 10/524,738, date of mailing February 6, 2008. *
	C22	Office Action, U.S. Application No. 10/524,738, date of mailing August 4, 2008. *
	C23	Advisory Action, U.S. Application No. 10/524,738, date of mailing January 29, 2009. *
	C24	Notice of Allowance, U.S. Application No. 10/524,738, date of mailing May 19, 2009. *
	C25	Issue Notification, U.S. Application No. 10/524,738, date of mailing September 19, 2009. *
	C26	Cao, Y., <i>et al.</i> , "Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells," <i>Int. J. Cancer</i> , 123:89-99 (2008).
	C27	Preliminary Amendment, U.S. Application No. 10/524,738, filed on February 16, 2005.*
	C28	Reply to Restriction Requirement, U.S. Application No. 10/524,738, filed on November 6, 2006.*
	C29	Reply to Office Action, U.S. Application No. 10/524,738, filed on June 14, 2007.*
	C30	Reply to Office Action, U.S. Application No. 10/524,738, filed on December 10, 2007.*
	C31	Reply to Office Action, U.S. Application No. 10/524,738, filed on May 6, 2008.*
	C32	Reply to Final Office Action, U.S. Application No. 10/524,738, filed on January 2, 2009.*
	C33	Amendment and Request for Continued Examination, U.S. Application No. 10/524,738, filed April 1, 2009.*

*Copies of any U.S. Office Communications or non-published U.S. Patent Applications are not being provided because the examiner has access to such documents through PAIR. We are not listing separately any prior U.S. Patent Office communications regarding the cited documents because the Examiner has access to any such actions through PAIR.

EXAMINER	DATE CONSIDERED
----------	-----------------